Cytek Biosciences Inc (CTKB)
Operating return on assets (Operating ROA)
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating income (ttm) | US$ in thousands | -27,846 | -27,625 | -19,845 | -11,609 | -1,804 | -571 | 966 | 5,668 | |||
| Total assets | US$ in thousands | 494,457 | 519,430 | 525,054 | 524,575 | 519,476 | 499,295 | 492,817 | 485,879 | 463,305 | 454,320 | 230,279 |
| Operating ROA | -5.63% | -5.32% | -3.78% | -2.21% | -0.35% | -0.11% | 0.20% | 1.17% |
December 31, 2023 calculation
Operating ROA = Operating income (ttm) ÷ Total assets
= $-27,846K ÷ $494,457K
= -5.63%
Cytek Biosciences Inc's operating return on assets (ROA) has been fluctuating over the past several quarters. From December 31, 2021, to March 31, 2022, the operating ROA increased from 0.20% to 1.17%, indicating a positive trend in the company's ability to generate operating income relative to its assets during this period. However, the trend reversed in subsequent quarters, with the operating ROA decreasing steadily to -5.63% by December 31, 2023.
The negative operating ROA numbers suggest that Cytek Biosciences Inc may be experiencing challenges in generating operating profits from its assets. It is important for the company to closely monitor and address the factors contributing to this trend to improve its operating efficiency and profitability in the future. Further analysis of the company's operating expenses, sales revenue, asset utilization, and overall business strategy may provide insights into the reasons behind the declining operating ROA.
Peer comparison
Dec 31, 2023